SummaryInflammatory conditions of the breast are an important group of diseases that can mimic breast carcinoma on clinical and radiological grounds. This pictorial essay presents the radiological and pathological features of some of these entities.
Key Words: Breast, MRI,Screening
Copyright: Deepika GunawardenaCorrespondence: Deepika Gunawardena, dsguna@yahoo.com Breast MRI is a powerful imaging tool with an excellent sensitivity around 94-100%, especially when double read, to detect cancers which are otherwise occult. However, lower specificity and high false positivity rates, demands histological confirmation of MRI only detected lesions to prevent possible over treatment. In order to maintain high standards and cost effectiveness of breast MRI, careful patient selection is as important as maintaining a meticulous technique or radiologist expertise. Breast MRI is useful at every phase of breast cancer management such as early detection, pre-operative staging, monitoring neo-adjuvant chemotherapy and identifying recurrences. This is a review on current best practice, for clinical applications of breast MRI.
Invasive lobular carcinoma (ILC) is the second most common histological sub type of breast cancer among women. Its' characteristic immuno-histopathology leads to less conspicuous clinical and radiological features resulting in delayed diagnosis. The difference between ILC and invasive ductal carcinoma (IDC) with respect to risk factors, clinical features, imaging appearances and metastases etc. has been overlooked for many years. In this article, we attempt to review the available literature on ILC emphasizing the difference from IDC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.